Research Compound Profile
Yohimbine Caffeine is a dual-compound thermogenic research blend manufactured by Magnus Pharmaceuticals, combining the alpha-2 adrenergic receptor antagonist yohimbine with the methylxanthine stimulant caffeine. This formulation enables comprehensive investigation of combined thermogenic pathways in laboratory settings. Researchers at Stroid UK Shop examine these compounds for their synergistic effects on lipolytic enzyme activation and cyclic adenosine monophosphate (cAMP) elevation in adipocyte models.
The yohimbine component functions as a selective alpha-2 adrenergic receptor antagonist, blocking inhibitory feedback mechanisms that normally suppress noradrenaline release. This mechanism enhances sympathetic nervous system activity in research models, particularly affecting pre-synaptic alpha-2 receptors in adipose tissue. Caffeine operates through multiple pathways including phosphodiesterase inhibition, adenosine receptor antagonism, and calcium mobilisation from intracellular stores. Scientists studying thermogenic compound combinations evaluate how these complementary mechanisms amplify metabolic rate elevation beyond individual compound effects.
Laboratory Applications
Research applications focus on thermogenesis modulation, lipolytic pathway activation, and metabolic rate enhancement in controlled laboratory environments. Investigators examine the compound’s effects on hormone-sensitive lipase activation, examining how yohimbine’s alpha-2 receptor antagonism combines with caffeine’s phosphodiesterase inhibition to elevate intracellular cAMP levels. Studies evaluate pre-adipocyte differentiation, brown adipose tissue activation markers, and uncoupling protein expression in cell culture systems. Metabolic researchers investigating energy expenditure pathways compare this dual-compound matrix against single-agent preparations. Additional research areas include sympathetic nervous system modulation studies and adrenergic receptor binding affinity investigations. Comparative analysis with selective androgen receptor modulators explores differential metabolic pathway activation mechanisms. Researchers also examine interactions with metabolic peptide compounds to understand multi-target therapeutic strategies.
Specifications
| Compound Classification | Dual thermogenic research blend |
|---|---|
| Active Components | Yohimbine HCl + Caffeine anhydrous |
| Manufacturer | Magnus Pharmaceuticals |
| Storage Requirements | Room temperature, dry environment |
| Research Applications | Thermogenesis, lipolysis, metabolic studies |
| Quality Control | Pharmaceutical-grade manufacturing standards |
Research Compliance
This yohimbine caffeine research product is manufactured by Magnus Pharmaceuticals exclusively for in-vitro laboratory investigations. Not approved for human consumption, therapeutic use, or clinical applications. Researchers must comply with institutional guidelines for handling thermogenic research compounds and maintain proper laboratory safety protocols during experimental procedures.
